Difference between revisions of "Zuclopenthixol MA-Lurasidone"
From Psychiatrienet
(Created page with '{{Drugswitch | from = Zuclopenthixol_MA | to = Lurasidone | stop = {{lastinjection}} | start = {{StartStand}} | info = {{Zuclopenthixol_MA}}{{RefSwitchToLurasidone}} | view = St...') |
(No difference)
|
Latest revision as of 14:56, 16 March 2015
| ||||||||||||||||||||
| ||||||||||||||||||||
Switch medication from Zuclopenthixol_MA to Lurasidone.[1] [2]
Stop Zuclopenthixol_MA - Day 1: Last depot injection
Start Lurasidone- Day 1-4: approx. 25% of target dose
- Day 5-8: approx. 50% of target dose
- Day 9-12: approx. 75% of target dose
- Day 13: target dose
More information- Zuclopenthixol_MA = Zuclopenthixol acetate [3]
- More information on switching to lurasidon: see reference. [4]
— Zuclopenthixol_MA — Lurasidone
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ SPC Zuclopenthixol acetate
- ↑ McEvoy JP et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.J Clin Psychiatry. 2013 Feb;74(2):170-9.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
